EXL Releases 2019 Sustainability Report

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a leading operations management and analytics company, today announced the release of its 2019 sustainability report. The report highlighted EXL’s strategies for promoting the health and growth potential of employees, responsibly managing its environment footprint, and positively impacting the communities in which it operates.

“As we confront historic new operational, social, and environmental challenges, we have all seen first-hand that agility, resilience, and sustainability are some of the most valuable commodities that a business can have,” stated Rohit Kapoor, Vice Chairman and Chief Executive Officer, EXL, within the report. “The experience of the last several months has forced us all to dig deeper, look harder at the status quo and commit ourselves to business strategies that foster growth beyond bottom line financial metrics.”

The report focuses on EXL’s sustainability measures across several key areas aligned with the United Nations’ Sustainable Development Goals. These areas include:

  • Business Integrity to ensure long-term success through corporate governance, ethics and business partner management
  • Our People to continuously train employees and create the next generation of leaders, as well as promote workforce diversity to foster an inclusive atmosphere
  • Environmental
    Stewardship to promote the efficient use of natural resources and minimize pollution
  • Operational Excellence to provide resilient high-quality services, implement innovative solutions and ensure data integrity
  • Community Engagement to drive positive social change across every geography and community in which EXL operates

The report was developed as per the Global Reporting Initiative Standards. To view the full report, please visit this link.

About EXL

EXL (NASDAQ: EXLS) is a leading operations management and analytics company that helps our clients build and grow sustainable businesses. By orchestrating our domain expertise, data, analytics and digital technology, we look deeper to design and manage agile, customer-centric operating models to improve global operations, drive profitability, enhance customer satisfaction, increase data-driven insights, and manage risk and compliance. Headquartered in New York, EXL has more than 31,800 professionals in locations throughout the United States, the UK, Europe, India, the Philippines, Colombia, Australia and South Africa. EXL serves multiple industries including insurance, healthcare, banking and financial services, utilities, travel, transportation and logistics, media and retail, among others. For more information, visit www.exlservice.com.



Media - US
Michael Sherrill
Vice President Marketing
646-419-0778
[email protected]

Media - Europe, India and APAC
Shailendra Singh
Vice President Corporate Communications
+91-98104-76075
[email protected]

Investor Relations
Steven N. Barlow
Vice President Investor Relations
212-624-5913
[email protected]

PDS Biotech Announces New and Broad Versamune® Platform Patent Claims

Granted methods patent for Versamune® platform by the United States Patent and Trademark Office

FLORHAM PARK, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has been granted U.S. Patent No. 10,828,364 titled “Method for Reducing a Myeloid Derived Suppressor Cell Population With Cationic Lipid Vaccine Compositions” by the United States Patent and Trademark Office (USPTO).

“The award of this patent provides broad protections for our Versamune® platform,” commented Dr. Frank Bedu-Addo, CEO of PDS Biotech. “Today, there are three active mid-stage clinical trials of our lead program, PDS0101 partnered with leaders in immuno-oncology, and we believe that the Versamune® platform may provide improved clinical outcomes for patients.”

The U.S. Patent No. 10,828,364 titled “Method for Reducing a Myeloid Derived Suppressor Cell Population With Cationic Lipid Vaccine Compositions” provides protection for the Versamune® platform including its chemical design and method of use. The patent covers methods for reduction of myeloid derived suppressor cell (MDSC) populations, which are known to suppress immune responses, by administering any positively charged (cationic) lipid combined with therapeutic factors including cytokines and interleukins. The patent also covers the combination of any cationic lipid and therapeutic factor to augment the anti-tumor immune response. The PDS Versamune® patent portfolio also includes broader cationic lipid compositions and methods of activating the immune system. The combination of Versamune® with various antigens forms the basis for PDS Biotech’s broad immuno-oncology pipeline, including its lead candidate PDS0101 for the treatment of advanced human papillomavirus (HPV) related cancers.

A portion of the work leading to this invention was carried out with support from the United States Government provided under the National Cancer Institute CRADA No. 2644. Therefore, the United States Government has certain rights in and to the present invention.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast.” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for its lead asset PDS0101; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: [email protected]

Jacob Goldberger
CG Capital
Phone: +1 (404) 736-3841
Email: [email protected]



Intellinetics, Inc. Reports Third Quarter and Nine Month Results


Record Software as a Service and Overall Revenue; 



Record Positive Net Income; Earnings per Share of $0.06

COLUMBUS, OH, Nov. 16, 2020 (GLOBE NEWSWIRE) — Intellinetics, Inc. (OTCQB: INLX), a cloud-based document solutions provider, announced financial results for the three and nine months ended September 30, 2020.

2020 Third Quarter Financial Highlights

  • Total Revenue increased 232% from the same period in 2019.
  • Software as a Service Revenue increased 32% from the same period in 2019.
  • Net Income of $155,673 compared to Net Loss of $398,753 from the same period in 2019.
  • Adjusted EBITDA of $374,614, an improvement of $467,447 compared to an adjusted EBITDA loss of $92,833 from the same period in 2019.
  • Earnings per share of $0.06.

2020 Nine Month Financial Highlights

  • Total Revenue increased 191% from the same period in 2019.
  • Software as a Service Revenue increased 18% from the same period in 2019.
  • Net Loss of $772,894 improved from a Net Loss of $1,542,268 from the same period in 2019.
  • Adjusted EBITDA of $441,774, an improvement of $989,501 compared to an adjusted EBITDA loss of $547,727 from the same period in 2019.

Summary – 2020 Third Quarter Results

Revenues for the three months ended September 30, 2020 were $2,511,282 as compared with $755,568 for the same period in 2019. The increase in our professional services and storage and retrieval services revenues is primarily due to the addition of revenues from our subsidiary, Graphic Sciences, Inc., acquired March 2, 2020, and the increase in software maintenance services is primarily due to the addition of revenues from the acquisition of the assets of CEO Imaging Systems, Inc. on April 24, 2020. Intellinetics reported net income of $155,673 for the three months ended September 30, 2020 and a net loss of $398,753 for the three months ended September 30, 2019, representing an improvement of $554,426. The improved net income results were primarily the result of improved operating results as well as lower interest expense. Basic and diluted net income per share for the three months ended September 30, 2020 and 2019 was $0.06 and $1.08, respectively.

Summary – 2020 Nine Month Results

Revenues for the nine months ended September 30, 2020 were $5,557,586 as compared with $1,911,561 for the same period in 2019. The increase in our professional services and storage and retrieval services revenues is primarily due to the addition of revenues from our recently-acquired subsidiary, Graphic Sciences, Inc., and the increase in software maintenance services is primarily due to the addition of revenues from the acquisition of the assets of CEO Imaging Systems, Inc. Intellinetics reported a net loss of $772,894 and $1,542,268 for the nine months ended September 30, 2020 and 2019, respectively, representing a decrease in net loss of $769,374. The decreased net loss was primarily the result of improved operating income contribution, as well as a gain on extinguishment of debt of $287,426, and income tax benefit of $188,300, offset by acquisition-related transaction costs of $636,440. Basic and diluted net loss per share for the nine months ended September 30, 2020 and 2019 was $0.34 and $4.17, respectively.

2020 Operational Highlights

  • Positive net income for three months ended September 30, 2020.
  • Positive adjusted EBITDA for three and nine months ended September 30, 2020. 
  • Integration of acquisitions of Graphic Sciences (March 2, 2020) and CEO Imaging Systems, Inc. (April 24, 2020) progressing at or ahead of schedule despite pandemic challenges.
  • Maintaining benefits for employees furloughed from March through June due to state stay-at-home orders, supported by temporary management salary reductions and other cost savings measures.


James F. DeSocio
, President & CEO of Intellinetics, stated, “I could not be more proud of our team for the grit and resolve demonstrated during the quarter. Their work is reflected in the continued rapid integration of our acquisitions, the relationships maintained with customers and prospects, and, critically, in our improved operating results. Together, we have delivered a positive net income at Intellinetics for the first quarter since our business began operating as a public company in 2012. We also are reporting our highest ever quarterly software as a service revenues and overall revenues. While we celebrate this achievement, we have our eyes on the future. The COVID pandemic is still affecting our customers and the way we all do business. As a result, we need to be creative and nimble in pursuing revenue streams from new and existing customers. 

“Our teams have been focused on exactly that, and we have bundled new packages and developed new solutions that help our customers better navigate their own challenges in an environment demanding increased distancing and remote work. One example is a bundled scanning and document solution for customers to transform their records from paper to the cloud, without ever being unable to access a critical document when needed.

“I am focused on sustaining the momentum we have achieved. We are maintaining our goal, set last quarter, to continue to deliver positive Adjusted EBITDA for the remainder of 2020. Similarly, despite the lingering pandemic, we expect to deliver revenues in the fourth quarter that are in line with our third quarter results.”

Conference Call

Intellinetics is holding a conference call to discuss these results on Monday, November 16, 2020, at 9:30 a.m. Eastern Time. The conference call can be accessed by dialing +1 929 205 6099 and providing passcode 81918576516#. If you are unable to participate during the live call, a replay of the conference call will be available approximately two hours after the completion of the call through November 30, 2020. To listen to the replay, the call will be archived on the company’s website at https://www.intellinetics.com/company-news/.

About Intellinetics, Inc.

Intellinetics, Inc., located in Columbus, Ohio, is a cloud-based document services software provider. Its IntelliCloud™ suite of solutions serve a mission-critical role for organizations in highly regulated, risk and compliance-intensive markets in Healthcare, K-12, Public Safety, Public Sector, Risk Management, Financial Services and beyond. IntelliCloud solutions make content secure, compliant, and process-ready to drive innovation, efficiencies and growth. Through its Image Technology Group and production scanning department, hundreds of millions of images have been converted from paper to digital, paper to microfilm, and microfiche to microfilm for business and federal, county, and municipal governments. Its operations in Madison Heights, Michigan, also provides its clients with long-term paper and microfilm storage and retrieval options. For additional information, please visit www.intellinetics.com.

Cautionary Statement

Statements in this press release which are not purely historical, including statements regarding future business and growth, future revenues, including fourth quarter revenues and future revenue streams from new and existing customers, fourth quarter Adjusted EBITDA, cash flow and other synergies associated with our recent acquisition of Graphic Sciences and CEO Imaging and the success of our integration efforts, our other product and service offerings and partnerships mentioned in this release, and in any other industry, market, initiative, service or innovation; cross-selling opportunities Intellinetics’ future revenues, revenue consistency, growth and long-term value, including trends in revenue growth and mix; growth of software as a service, professional services, and maintenance revenue; market penetration; execution of Intellinetics’ business plan, strategy, direction and focus; and other intentions, beliefs, expectations, representations, projections, plans or strategies regarding future growth, financial results, and other future events are forward-looking statements. The forward-looking statements involve risks and uncertainties including, but not limited to, the risks associated with the effect of changing economic conditions, the impact of COVID-19 and related governmental actions and orders on customers, suppliers, employees and the economy and our industry, Intellinetics’ ability to execute on its business plan and strategy, customary risks attendant to acquisitions, trends in the products markets, variations in Intellinetics’ cash flow or adequacy of capital resources, market acceptance risks, the success of Intellinetics’ solutions providers, including human services, health care, and education, technical development risks, and other risks, uncertainties and other factors discussed from time to time in its reports filed with or furnished to the Securities and Exchange Commission, including in Intellinetics’ most recent annual report on Form 10-K as well as subsequently filed reports on Form 8-K. Intellinetics cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Intellinetics disclaims any obligation and does not undertake to update or revise any forward-looking statements in this press release. Expanded and historical information is made available to the public by Intellinetics on its website at www.intellinetics.com or at www.sec.gov.

CONTACT:

Joe Spain, CFO
Intellinetics, Inc.
614.921.8170 [email protected]

Non-GAAP Financial Measure

Intellinetics uses non-GAAP Adjusted EBITDA as a supplemental measure of our performance that is not required by, or presented in accordance with, accounting principles generally accepted in the United States (GAAP).

A non-GAAP financial measure is a numerical measure of a company’s financial performance that excludes or includes amounts so as to be different from the most directly comparable measure calculated and presented in accordance with GAAP in the statement of income, balance sheet or statement of cash flows of a company. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be considered as an alternative to net income, operating income, or any other performance measure derived in accordance with GAAP, or as an alternative to cash flow from operating activities or a measure of our liquidity. Intellinetics urges investors to review the reconciliation of non-GAAP Adjusted EBITDA to the comparable GAAP Net Loss, which is included in this press release, and not to rely on any single financial measure to evaluate Intellinetics’ financial performance.

We believe that Adjusted EBITDA is a useful performance measure and is used by us to facilitate a comparison of our operating performance on a consistent basis from period-to-period and to provide for a more complete understanding of factors and trends affecting our business than measures under GAAP can provide alone. We define “Adjusted EBITDA” as earnings before interest expense, any income taxes, depreciation and amortization expense, stock-based compensation, note conversion and note or equity offer warrant or stock expense, gain or loss on debt extinguishment, and significant transaction costs.

Reconciliation of Net Income (Loss) to Adjusted EBITDA

    For the Three Months Ended September 30,  
    2020     2019  
Net income (loss) – GAAP   $ 155,673     $ (398,753 )
Interest expense, net     115,497       245,156  
Depreciation and amortization     89,475       1,901  
Stock-based compensation     13,969       58,863  
Adjusted EBITDA   $ 374,614     $ (92,833 )

    For the Nine Months Ended September 30,  
    2020     2019  
Net loss – GAAP   $ (772,894 )   $ (1,542,268 )
Interest expense, net     522,724       717,650  
Significant transaction costs     495,440        
Stock and warrant issue expense     377,761        
Depreciation and amortization     204,317       5,908  
Stock-based compensation     90,152       270,983  
Income tax benefit, net     (188,300 )      
Gain on extinguishment of debt     (287,426 )      
Adjusted EBITDA   $ 441,774     $ (547,727 )

2020 Second Quarter Adjusted EBITDA Corrections

The following tables reflect corrections to our 2020 Second Quarter Adjusted EBITDA amounts, as reported in our earnings release dated August 14, 2020. Our Adjusted EBITDA for the three and six month periods ended June 30, 2020 were $59,374 and $67,160, respectively, and the Adjusted EBITDA reconciliation tables for such periods, as corrected, are fully set forth below. There are no errors or corrections in our historical GAAP financial information for the same periods as reported, as these errors in the computation of our Adjusted EBITDA calculation for those periods did not affect the computation or reporting of our Net Loss or any other historical financial information for those periods. 

In addition, commencing with the second quarter results, we have included significant transaction costs as an adjustment to EBITDA.

For the Three Months Ended June 30, 2020:

Significant transaction costs was changed from $175,673 to $131,073, and Adjusted EBITDA was changed from $103,974 to $59,374.

    For the Three Months Ended June 30,  
    2020     2019  
Net loss – GAAP   $ (282,356 )   $ (473,662 )
Significant transaction costs     131,073        
Interest expense, net     116,796       239,347  
Depreciation and amortization     86,751       2,099  
Stock-based compensation     7,110       68,496  
Adjusted EBITDA   $ 59,374     $ (163,720 )

For the Six Months Ended June 30, 2020:
Significant transaction costs was changed from $636,440 to $495,440, interest expense was changed from $583,331 to $407,227, and Adjusted EBITDA was changed from $384,264 to $67,160.

    For the Six Months Ended June 30,  
    2020     2019  
Net loss – GAAP   $ (928,567 )   $ (1,143,515 )
Significant transaction costs     495,440        
Interest expense, net     407,227       472,494  
Income tax benefit, net     (188,300 )      
Depreciation and amortization     114,842       4,007  
Stock-based compensation     76,183       212,120  
Stock and warrant issue expense     377,761        
Gain on extinguishment of debt     (287,426 )      
Adjusted EBITDA   $ 67,160     $ (454,894 )



INTELLINETICS, INC. and SUBSIDIARY

Condensed Consolidated Statements of Operations

(Unaudited)

    For the Three Months Ended
September 30,
    For the Nine Months Ended
September 30,
 
    2020     2019     2020     2019  
                         
Revenues:                                
Sale of software   $ 53,767     $ 170,738     $ 153,999     $ 179,590  
Software as a service     281,810       214,237       756,497       643,402  
Software maintenance services     340,129       248,343       915,483       753,692  
Professional services     1,615,445       122,250       3,221,154       334,877  
Storage and retrieval services     220,131             510,453        
Total revenues     2,511,282       755,568       5,557,586       1,911,561  
                                 
Cost of revenues:                                
Sale of software           1,469       40,117       4,479  
Software as a service     65,712       67,643       209,508       195,911  
Software maintenance services     49,354       17,894       127,439       67,813  
Professional services     841,016       60,684       1,637,308       152,056  
Storage and retrieval services     64,906             136,283        
Total cost of revenues     1,020,988       147,690       2,150,655       420,259  
                                 
Gross profit     1,490,294       607,878       3,406,931       1,491,302  
                                 
Operating expenses:                                
General and administrative     844,186       510,817       2,533,046       1,570,835  
Significant transaction costs                 636,440        
Sales and marketing     285,462       248,757       759,024       739,177  
Depreciation and amortization     89,475       1,901       204,317       5,908  
                                 
Total operating expenses     1,219,123       761,475       4,132,827       2,315,920  
                                 
Income (loss) from operations     271,171       (153,597 )     (725,896 )     (824,618 )
                                 
Other income (expense)                                
Gain on extinguishment of debt                 287,426        
Income tax benefit                 188,300        
Interest expense, net     (115,498 )     (245,156 )     (522,724 )     (717,650 )
                                 
Total other expense     (115,498 )     (245,156 )     (46,998 )     (717,650 )
                                 
Net income (loss)   $ 155,673     $ (398,753 )   $ (772,894 )   $ (1,542,268 )
                                 
Basic and diluted net income (loss) per share:   $ 0.06     $ (1.08 )   $ (0.34 )   $ (4.17 )
                                 
Weighted average number of common shares outstanding – basic and diluted     2,810,865       370,497       2,271,169       370,205  



INTELLINETICS, INC. and SUBSIDIARY

Condensed Consolidated Balance Sheets

    (Unaudited)        
    September 30,     December 31,  
    2020     2019  
             
ASSETS  
Current assets:                
Cash   $ 1,511,990     $ 404,165  
Accounts receivable, net     1,078,862       329,571  
Accounts receivable, unbilled     503,642       23,371  
Parts and supplies, net     79,975       4,184  
Prepaid expenses and other current assets     207,201       110,841  
Total current assets     3,381,670       872,132  
                 
Property and equipment, net     716,000       6,919  
Right of use assets     2,703,978       97,239  
Intangible assets, net     1,239,090        
Goodwill     2,322,887        
Other assets     18,784       10,284  
Total assets   $ 10,382,409     $ 986,574  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY(DEFICIT)  
                 
Current liabilities:                
Accounts payable   $ 183,327     $ 160,911  
Accrued compensation     261,638       70,027  
Accrued expenses, other     156,567       140,079  
Lease liabilities – current     516,206       47,397  
Deferred revenues     1,022,252       754,073  
Deferred compensation     100,828       117,166  
Earnout liabilities – current     287,390        
Accrued interest payable – current     4,505       1,212,498  
Notes payable – current     612,539       3,339,963  
Notes payable – related party – current           1,467,400  
Total current liabilities     3,145,252       7,309,514  
                 
Long-term liabilities:                
Notes payable     1,817,681        
Lease liabilities – net of current portion     2,262,445       53,318  
Earnout liabilities – net of current portion     601,810        
Total long-term liabilities     4,681,936       53,318  
Total liabilities     7,827,188       7,362,832  
                 
Stockholders’ equity (deficit):                
Common stock, $0.001 par value, 25,000,000 shares authorized; 2,810,865 and 370,497 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively     2,811       371  
Additional paid-in capital     24,121,370       14,419,437  
Accumulated deficit     (21,568,960 )     (20,796,066 )
Total stockholders’ equity (deficit)     2,555,221       (6,376,258 )
Total liabilities and stockholders’ equity (deficit)   $ 10,382,409     $ 986,574  



INTELLINETICS, INC. and SUBSIDIARY

Condensed Consolidated Statements of Cash Flows

(Unaudited)

    For the Nine Months Ended September 30,  
    2020     2019  
             
Cash flows from operating activities:                
Net loss   $ (772,894 )   $ (1,542,268 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     204,317       5,908  
Bad debt expense     40,325       14,340  
Parts and supplies reserve change     10,500        
Amortization of deferred financing costs     91,156       137,888  
Amortization of beneficial conversion option     11,786       53,038  
Amortization of debt discount     62,222        
Amortization of right of use asset     278,879       30,982  
Stock issued for services     57,500       87,500  
Stock options compensation     32,652       183,483  
Note conversion stock issue expense     141,000        
Warrant issue expense     236,761        
Interest on converted debt     176,106        
Gain on extinguishment of debt     (287,426 )      
Amortization of original issue discount on notes     18,296        
Changes in operating assets and liabilities:                
Accounts receivable     333,121       (227,594 )
Accounts receivable, unbilled     (204,248 )     29,766  
Parts and supplies     5,105       1,533  
Prepaid expenses and other current assets     (25,790 )     4,155  
Right of use assets     0       (138,549 )
 Accounts payable and accrued expenses     (589,461 )     65,798  
Lease liabilities, current and long-term     (269,748 )     111,476  
Deferred compensation     (16,338 )     (35,077 )
Accrued interest, current and long-term     4,504       523,085  
Deferred revenues     69,520       (50,903 )
Total adjustments     380,739       796,829  
Net cash used in operating activities     (392,155 )     (745,439 )
                 
Cash flows from investing activities:                
Cash paid to acquire business, net of cash acquired     (4,019,098 )      
      0        
Purchases of property and equipment     (55,603 )     (5,489 )
Net cash used in investing activities     (4,074,701 )     (5,489 )
                 
Cash flows from financing activities:                
Proceeds from issuance of common stock     3,167,500        
Offering costs paid on issuance of common stock     (307,867 )      
Payment of deferred financing costs     (175,924 )      
Proceeds from notes payable     3,008,700        
Repayment of notes payable     (70,000 )      
Repayment of notes payable – related parties     (47,728 )     (34,622 )
Net cash provided by/(used in) financing activities     5,574,681       (34,622 )
                 
Net increase (decrease) in cash     1,107,825       (785,550 )
Cash – beginning of period     404,165       1,088,630  
Cash – end of period   $ 1,511,990     $ 303,080  
                 
Supplemental disclosure of cash flow information:                
Cash paid during the period for interest           $ 6,241  
Cash paid during the period for taxes   $ 142,018     $  
                 
Supplemental disclosure of non-cash financing activities:                
Accrued interest notes payable converted to equity   $ 796,074     $  
Accrued interest notes payable related parties converted to equity     238,883        
Discount on notes payable for beneficial conversion feature     320,000        
Discount on notes payable for warrants     135,292        
Notes payable converted to equity     3,421,063        
Notes payable converted to equity – related parties     1,465,515        
                 
Supplemental disclosure of non-cash investing activities relating to business acquisitions:                
Cash   $ 17,269     $  
Accounts receivable     1,122,737        
Accounts receivable, unbilled     276,023        
Parts and supplies     91,396        
Prepaid expenses     73,116        
Other current assets     5,954        
Right of use assets     2,885,618        
Property and equipment     735,885        
Intangible assets     1,361,000        
Accounts payable     (168,749 )      
Accrued expenses     (162,426 )      
Lease liabilities     (2,947,684 )      
Federal and state taxes payable     (168,900 )      
Deferred revenues     (198,659 )      
Deferred tax liabilities, net     (149,900 )      
Net assets acquired in acquisition     2,772,680        
Total goodwill acquired in acquisition     2,322,887        
Total purchase price of acquisition     5,095,567        
Purchase price of business acquisition financed with earnout liability     (889,200 )      
Purchase price of business acquisition financed with installment payments     (170,000 )      
Cash used in business acquisition   $ 4,036,367     $  



Duke Energy named one of North America’s top sustainable companies for 15th straight year

PR Newswire

CHARLOTTE, N.C., Nov. 16, 2020 /PRNewswire/ — With its expansion of renewable energy and significant reduction in carbon emissions, combined with its continued focus on social responsibility, Duke Energy was recently named to the Dow Jones Sustainability Index (DJSI) for North America for the 15th consecutive year.

“Trust begins with transparency and our stakeholders want to see our progress on the environmental, social and governance topics that matter most,” said Katherine Neebe, Duke Energy’s chief sustainability officer and president, Duke Energy Foundation. “As we focus on delivering affordable, reliable and increasingly clean energy for our customers and communities, it’s an honor to be named to the Dow Jones Sustainability Index for 15 straight years.”

Since 1999, the DJSI has evaluated the sustainability of leading companies worldwide.

In selecting the top performers in each business sector, the DJSI reviews companies on several general and industry-specific topics related to economic, environmental and social dimensions.

Among the topics are corporate governance, innovation management, environmental policy, climate strategy, human capital development and corporate citizenship.

The index is compiled annually by S&P Dow Jones and S&P Global.

Since 2007, Duke Energy has published an annual Sustainability Report that summarizes its efforts to advance energy efficiency, develop renewable energy, reduce emissions and more.

The 2019 report is available online.

Some of the company’s environmental, social and governance highlights:

Duke Energy

Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of the largest energy holding companies in the U.S. It employs 30,000 people and has an electric generating capacity of 51,000 megawatts through its regulated utilities, and 3,000 megawatts through its nonregulated Duke Energy Renewables unit.

Duke Energy is transforming its customers’ experience, modernizing the energy grid, generating cleaner energy and expanding natural gas infrastructure to create a smarter energy future for the people and communities it serves. The Electric Utilities and Infrastructure unit’s regulated utilities serve approximately 7.7 million retail electric customers in six states – North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky. The Gas Utilities and Infrastructure unit distributes natural gas to more than 1.6 million customers in five states – North Carolina, South Carolina, Tennessee, Ohio and Kentucky. The Duke Energy Renewables unit operates wind and solar generation facilities across the U.S., as well as energy storage and microgrid projects.

Duke Energy was named to Fortune’s 2020 “World’s Most Admired Companies” list, and Forbes’ 2019 “America’s Best Employers” list. More information about the company is available at duke-energy.com. The Duke Energy News Center contains news releases, fact sheets, photos, videos and other materials. Duke Energy’s illumination features stories about people, innovations, community topics and environmental issues. Follow Duke Energy on Twitter, LinkedIn, Instagram and Facebook.

Contact: Randy Wheeless 
24-Hour: 800.559.3853
Twitter: @DE_RandyW

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/duke-energy-named-one-of-north-americas-top-sustainable-companies-for-15th-straight-year-301173612.html

SOURCE Duke Energy

Baxter Publishes Its First Sustainability Accounting Standards Board (SASB) Index and Celebrates Continued Inclusion in the Dow Jones Sustainability Indices (DJSI)

Baxter Publishes Its First Sustainability Accounting Standards Board (SASB) Index and Celebrates Continued Inclusion in the Dow Jones Sustainability Indices (DJSI)

Company announces latest expansion of its corporate responsibility disclosures as it achieves top recognition in the annual DJSI

DEERFIELD, Ill.–(BUSINESS WIRE)–
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today published its first Sustainability Accounting Standards Board (SASB) index, a voluntary public disclosure that provides transparent and relevant corporate responsibility information to investors and other key stakeholders. This reporting milestone comes as Baxter is again named to the Dow Jones Sustainability Indices (DJSI), both DJSI World and DJSI North America, recognizing the company’s leading sustainability efforts. Baxter has proudly been included in the DJSI World and DJSI North America each year since they launched, in 1999 and 2005, respectively.

“As we strive to address the environmental, social and governance issues that matter most to our stakeholders, transparency is key—and has been a cornerstone of our work for decades,” said José (Joe) E. Almeida, chairman and chief executive officer. “This includes demonstrating the connection between our corporate responsibility initiatives and our business priorities. We are proud of the increasing sophistication of our sustainability efforts and will continue to evolve and broaden our disclosures to best meet stakeholder interests and needs.”

Baxter’s Inaugural Sustainability Accounting Standards Board (SASB) Index

Businesses, shareholders and stakeholders at large acknowledge that sustainability factors can affect a company’s long-term financial performance. SASB provides industry-specific metrics for sustainability topics, giving companies a platform to share relevant, standardized and easily accessible information incorporating responses to all or some of the applicable metrics. Baxter’s first index aligns with SASB’s Medical Equipment and Supplies Sustainability Accounting Standard and provides information on five topics: Affordability and Pricing, Product Safety, Ethical Marketing, Product Design and Lifecycle Management, and Supply Chain Management. Moving forward, Baxter expects to include a SASB index in the company’s annual Corporate Responsibility Report.

Continued Leadership in the Dow Jones Sustainability Indices (DJSI)

The DJSI evaluate leading sustainability-driven companies on the performance of their economic, environmental and social efforts, enabling investors to integrate sustainability considerations into their portfolios and serving as globally recognized designations of the most sustainable companies. In the recently announced 2020 lists, Baxter scored in the top four percent of companies assessed within the health care equipment and supplies industry, with leading performance in environmental reporting, marketing practices, materiality, policy influence and social reporting.

Baxter’s corporate responsibility strategy continues to drive the sustainability of products and operations, improve access to healthcare for the underserved and foster a best place to work. In June, the company published its 2019 Corporate Responsibility Report, which highlights progress related to Baxter’s 2015-2020 corporate responsibility priorities and goals. As Baxter nears the conclusion of this current set of goals, the company is developing its focus areas moving forward and remains committed to proactively evaluating its reporting approach. Baxter expects to announce its next set of corporate responsibility goals during the first half of 2021.

About Corporate Responsibility at Baxter: Making a Meaningful Difference Worldwide

Responsible corporate citizenship advances Baxter’s aspirations as a healthcare leader, sparks innovation globally and reinforces the dedication of our employees to doing business the right way. We have been honored for our efforts as an employer of choice and a socially responsible and sustainable business, and are privileged to be included on various lists such as 3BL Media’s 100 Best Corporate Citizens, the Dow Jones Sustainability Indices, Forbes and JUST Capital’s America’s “Most Just” companies, and the FTSE4Good Index, among numerous other regional and country-specific recognitions across the globe. Learn more about Baxter’s corporate responsibility initiatives here.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

This release includes forward-looking statements concerning Baxter’s expectations about future SASB disclosures. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in law and regulations; and other risks identified in Baxter’s most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.

Baxter is a registered trademark of Baxter International Inc.

Media

Bess Featherstone, (224) 948-5353

[email protected]

Investors

Clare Trachtman, (224) 948-3020

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Philanthropy Health Environment Other Health Other Philanthropy General Health

MEDIA:

Logo
Logo

Exagen and GSK partner for 4th straight year, driving greater awareness of challenges facing lupus diagnosis and management

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world’s leading healthcare companies, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus. At the center of the program are the proprietary AVISE® laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential.

This extension follows a similar one-year extension that Exagen and GSK entered into last year, and will continue to support the shared goal of helping SLE patients shorten the time to their diagnosis, which is nearly six years on average, and to facilitate improved patient outcomes.

Ron Rocca, President and CEO of Exagen shared, “We’re pleased to continue working with GSK, which demonstrates our ability to collaborate with major pharmaceutical companies in a shared commitment to improve patients’ lives. Having access to advanced test result data such as the AVISE® tests can support diagnosis, prognosis, and monitoring of challenging conditions like SLE.”

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients. For more information, please visit www.Exagen.com.

About GSK

GSK – a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.

Forward Looking Statements

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the expected benefits or results of Exagen’s collaboration with GSK, and the performance the AVISE® laboratory tests and benefits of the test results data obtained therefrom. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect our business, financial condition and results of operations, including as a result of shutdowns of our facilities and operations as well as those of our suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving our tests; the company’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community; the company’s ability to successfully execute on its Dx/Rx strategy, including its promotion efforts for SIMPONI®; third party payers not providing coverage and adequate reimbursement for the company’s testing products or promoted therapeutics; the company’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting the company’s business; and other risks described in the company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investors

Westwicke Partners
Mike Cavanaugh
[email protected]
646.677.1838

Company

Exagen Inc.
Kamal Adawi, Chief Financial Officer
[email protected]
760.477.5514



Avolon Announces Debt Tender Offers

Avolon Announces Debt Tender Offers

DUBLIN–(BUSINESS WIRE)–
Avolon Holdings Limited (“Avolon” or the “Company”), the international aircraft leasing company, announced today that each of Avolon Holdings Funding Limited, a Cayman Islands exempted company and a direct wholly-owned subsidiary of Avolon (“Avolon Holdings Funding”) and Park Aerospace Holdings Limited, a Cayman Islands exempted company and a direct wholly-owned subsidiary of Avolon (“Park” and, together with Avolon Holdings Funding, the “Offerors” each an “Offeror” and, together with the Company and its consolidated subsidiaries, “we,” “our” or “us”), offers to purchase for cash the notes issued by such Offeror, as applicable, listed in the following table (the “Notes”) (i) in accordance with, and in the order of, the corresponding Acceptance Priority Levels (as defined below) and (ii) subject to the Maximum Tender Cap (as defined below), any applicable Series Cap (as defined below) and possible pro rata allocation, upon the terms and subject to the conditions set forth in the Offer to Purchase (as defined below) including the Financing Condition (as defined below). The offers to purchase with respect to each series of Notes are referred to herein as the “Offers” and each, an “Offer.” Each Offer is made upon the terms and subject to the conditions set forth in the offer to purchase, dated November 16, 2020 (as may be amended or supplemented from time to time, the “Offer to Purchase”). Capitalized terms used but not defined in this press release have the meanings given to them in the Offer to Purchase.

Issuer

Title of

Security

Security Identifiers

Principal

Amount

Outstanding

Acceptance

Priority

Level

Series Cap

Early

Tender

Premium
(1)

Reference

Security

Bloomberg

Reference

Page

Fixed Spread(2)

Hypothetical

Total

Consideration(3)

Park

5.250% Notes due

2022*

CUSIP: 70014L AA8/ G6935L AA1

ISIN: US70014LAA89/ USG6935LAA10

$1,775,854,000

1

$350 million

aggregate

purchase

price

$30.00

0.125% UST due 10/31/2022

FIT1

220 bps

$1,045.32

Avolon Holdings Funding

3.625% senior notes due 2022*

CUSIP: 05401AAE1/ G0686BAD1 ISIN: US05401AAE10/ USG0686BAD13

$646,381,000

2

$100 million

aggregate

purchase

price

$30.00

0.125% UST due 10/31/2022

FIT1

205 bps

$1,018.22

Avolon Holdings Funding

5.500% Notes due 2023*

CUSIP: 05401A AA9/ G0686B AA7

ISIN: US05401AAA97/ USG0686BAA73

$462,590,000

3

$50 million aggregate purchase price

$30.00

0.250% UST due 11/15/2023

FIT1

315 bps

$1,041.33

* Admitted to trading on the Irish Stock Exchange plc, trading as Euronext Dublin (“Euronext Dublin”).

(1) Per $1,000 principal amount of Notes validly tendered and not validly withdrawn and accepted for purchase in the applicable Offer at or prior to the Early Tender Deadline; included in Total Consideration.

(2) Includes the Early Tender Premium (as defined herein).

(3) Hypothetical Total Consideration per $1,000 principal amount of Notes validly tendered and not validly withdrawn and accepted for purchase in the applicable Offer, based on a hypothetical Tender Offer Yield (as defined herein) determined as of 10:00 A.M., New York City time, on November 13, 2020 and assuming an Early Settlement Date (as defined herein) of December 3, 2020 for each Series. The actual Tender Offer Yield used to determine the actual Total Consideration for each Series will be calculated on the Price Determination Date (as defined herein). This information is provided for illustrative purposes only. We make no representation with respect to the actual Total Consideration that may be paid with respect to each Series and such amounts may be greater or less than those shown depending on the Tender Offer Yield as of the Price Determination Date. The Total Consideration will be determined taking into account the par call date, if applicable, for such Series (as defined herein). Excludes Accrued Interest (as defined herein).

All documentation relating to the Offers, including the Offer to Purchase, together with any updates, are available from the Information Agent and the Tender Agent, as set forth below. The Offer Documents can also be accessed at the following website: https://www.gbsc-usa.com/avolon/. The Offer to Purchase sets forth a complete description of the terms and conditions of the Offers. Holders of the Notes (“Holders”) are urged to read the Offer to Purchase carefully before making any decision with respect to the Offers.

Purpose of the Offers

The primary purpose of the Offers is to acquire the maximum principal amount of Notes for which the aggregate purchase price (including principal and premium, but excluding Accrued Interest) for the Notes does not exceed $500,000,000 (the “Maximum Tender Cap”) or any applicable Series Cap set forth in the table above (each, a “Series Cap”), subject to the satisfaction or waiver by us of the conditions set forth below and as further described in the Offer to Purchase. Notes that are accepted in the Offers will be purchased, retired and cancelled and will no longer remain outstanding obligations of the applicable Offeror. Such Notes will also be delisted from Euronext Dublin.

Details of the Offers

The Offers will expire at 11:59 p.m., New York City time, on December 15, 2020 (as the same may be extended with respect to any Offer, the “Expiration Date”). Holders must validly tender and not validly withdraw their Notes at or prior to 5:00 p.m., New York City time, on December 1, 2020 (as the same may be extended with respect to any Offer, the “Early Tender Deadline”), to be eligible to receive the applicable Total Consideration and Holders who validly tender their Notes after the Early Tender Deadline and at or prior to the Expiration Date will be eligible to receive only the applicable Purchase Price, which is equal to the applicable Total Consideration less the applicable Early Tender Premium, in each case as fully described in the Offer to Purchase. Tendered Notes may be withdrawn at any time at or prior to 5:00 p.m., New York City time, on December 1, 2020 (as the same may be extended with respect to any Offer, the “Withdrawal Deadline”), but not thereafter, except as required by applicable law as described in the Offer to Purchase. None of the Offers is conditioned upon consummation of any of the other Offers, and each Offer otherwise operates independently from the other Offers. None of the Offers is conditioned on any minimum amount of Notes being tendered.

The applicable Total Consideration for each $1,000 in principal amount of Notes validly tendered and not validly withdrawn before the Early Tender Deadline and accepted for purchase pursuant to the Offers will be determined by reference to a fixed spread specified for each Series of Notes over the yield based on the bid price of the applicable Reference Security specified in the table above for such Series, as fully described in the Offer to Purchase. The consideration will be calculated by the Dealer Managers (as defined below) at 10:00 A.M., New York City time, on December 2, 2020 (as the same may be extended with respect to any Offer, the “Price Determination Date”). The applicable Early Tender Premium for each Series of Notes is set forth in the table above. The Purchase Price for the Notes accepted for purchase pursuant to the Offers will be calculated by taking the applicable Total Consideration for such Series of Notes and subtracting from it the applicable Early Tender Premium for such Series of Notes. In addition to the applicable Total Consideration or applicable Purchase Price, as the case may be, accrued and unpaid interest from the last interest payment date up to, but not including, the applicable Settlement Date will be paid in cash on all validly tendered Notes accepted for purchase in the Offers (the “Accrued Interest”).

We reserve the right, but are under no obligation, at any point after the Early Tender Deadline and prior to the Expiration Date, to accept for purchase Notes that have been validly tendered and not validly withdrawn at or prior to the Early Tender Deadline on a date determined at our option (such date, if any, the “Early Settlement Date”). The Total Consideration, plus Accrued Interest, for Notes that are validly tendered and not validly withdrawn at or prior to the Early Tender Deadline and accepted for purchase will be paid by us in same-day funds on such Early Settlement Date, if any. We currently expect the Early Settlement Date, if any, to occur on December 3, 2020. The Purchase Price, plus Accrued Interest, for Notes that are validly tendered and not validly withdrawn after the Early Tender Deadline and at or prior to the Expiration Date and accepted for purchase will be paid by us in same-day funds promptly following the Expiration Date (the “Final Settlement Date”). We currently expect the Final Settlement Date to occur promptly following the Expiration Date, on December 17, 2020.

Our obligation to accept for purchase, and to pay for, Notes that are validly tendered and not validly withdrawn pursuant to each Offer, up to the Maximum Tender Cap and any applicable Series Cap, is conditioned on the satisfaction or waiver by us of a number of conditions set forth in the Offer to Purchase, including our receipt prior to the Expiration Date (or Early Settlement Date, if we elect to have an early settlement) of gross proceeds of at least $500,000,000 from our contemporaneous offering of one or more series of notes upon the terms and subject to the conditions contained in the prospectus related to such offering, on terms satisfactory to us in our sole discretion (the “Financing Condition”), in each case unless waived by us as provided in the Offer to Purchase.

The amounts of each Series of Notes that are accepted for purchase in the Offer will be determined in accordance with the priorities identified in the column “Acceptance Priority Level” in the table above. Subject to the Maximum Tender Cap and any applicable Series Cap, all Notes validly tendered and not validly withdrawn at or prior to the Early Tender Deadline having a higher Acceptance Priority Level will be accepted for purchase before any validly tendered and not validly withdrawn Notes having a lower Acceptance Priority Level, and all Notes validly tendered after the Early Tender Deadline and at or prior to the Expiration Date having a higher Acceptance Priority Level will be accepted for purchase before any Notes tendered after the Early Tender Deadline and at or prior to the Expiration Date having a lower Acceptance Priority Level. However, any Notes validly tendered and not validly withdrawn at or before the Early Tender Deadline will be accepted for purchase in priority to Notes validly tendered after the Early Tender Deadline and at or prior to the Expiration Date even if the Notes tendered after the Early Tender Deadline and at or prior to the Expiration Date have a higher Acceptance Priority Level than the Notes validly tendered and not validly withdrawn at or before the Early Tender Deadline. Notes of the Series in each Acceptance Priority Level accepted for purchase in accordance with the terms and conditions of the Offers may be subject to proration such that we will only accept for purchase Notes with an aggregate purchase price up to the Maximum Tender Cap or any applicable Series Cap.

We expressly reserve the right, in our sole discretion, to amend, extend or, upon failure of any condition described in the Offer to Purchase to be satisfied or waived (including the Financing Condition), to terminate any of the Offers, including the right to amend or eliminate the Maximum Tender Cap or any applicable Series Cap, at any time at or prior to the Expiration Date.

Deutsche Bank Securities Inc., Mizuho Securities USA LLC and Wells Fargo Securities, LLC are serving as the Lead Dealer Managers, and Barclays Capital Inc., BNP Paribas Securities Corp. and MUFG Securities Americas Inc. are serving as Co-Dealer Managers, in connection with the Offers (collectively, the “Dealer Managers”). Questions regarding terms and conditions of the Offers should be directed to Deutsche Bank Securities, Inc. by calling toll free at 866-627-0391, Mizuho Securities USA LLC by calling toll free at 866-271-7403 or to Wells Fargo Securities, LLC by calling toll free at 800-645-3751.

Global Bondholder Services Corporation has been appointed as information agent (the “Information Agent”) and tender agent (the “Tender Agent”) in connection with the Offers. Questions or requests for assistance in connection with the Offers or the delivery of tender instructions, or for additional copies of the Offer to Purchase, may be directed to Global Bondholder Services Corporation by calling collect at 212-430-3774 (for banks and brokers) or toll free at 866-924-2200. (for all others) or via e-mail at [email protected]. You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Offers. The Offer to Purchase can also be accessed at the following website: https://www.gbsc-usa.com/avolon/.

None of Avolon Holdings Funding, Park, the Company, the Dealer Managers, Global Bondholder Services Corporation, the trustee under the indenture governing the Notes or any of their respective affiliates is making any recommendation as to whether Holders should tender any Notes in response to the Offers. Holders must make their own decision as to whether to tender any of their Notes and, if so, the principal amounts of Notes to tender.

This press release is for informational purposes only and is not an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities. Neither this press release nor the Offer to Purchase, or the electronic transmission thereof, constitutes an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities, as applicable, in any jurisdiction in which, or to or from any person to or from whom, it is unlawful to make such offer or solicitation under applicable securities laws or otherwise. The distribution of this press release in certain jurisdictions may be restricted by law. In those jurisdictions where the securities, blue sky or other laws require the Offers to be made by a licensed broker or dealer and the Dealer Managers or any of their respective affiliates is such a licensed broker or dealer in any such jurisdiction, the Offers shall be deemed to be made by the Dealer Managers or such affiliate, as the case may be, on behalf of the Company in such jurisdiction.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014

This announcement is released by the Offerors (as defined below) and may contain inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (“MAR”), encompassing information relating to the Notes (as defined below). For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/155, this announcement is made by the directors of each Offeror.

About Avolon

Headquartered in Ireland, with offices in the United States, Dubai, Singapore, Hong Kong and Shanghai, Avolon provides aircraft leasing and lease management services. Avolon is 70% owned by an indirect subsidiary of Bohai Leasing Co., Ltd., a public company listed on the Shenzhen Stock Exchange (SLE: 000415) and 30% owned by ORIX Aviation Systems, a subsidiary of ORIX Corporation which is listed on the Tokyo and New York Stock Exchanges (TSE: 8591; NYSE: IX). Avolon is the world’s third largest aircraft leasing business with an owned, managed and committed fleet, as of 30 September 2020 of 837 aircraft.

Website: www.avolon.aero

Twitter: @avolon_aero

Note Regarding Forward-Looking Statements

This document includes forward-looking statements, beliefs or opinions, including statements with respect to Avolon’s business, financial condition, results of operations and plans. These forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond our control and all of which are based on our management’s current beliefs and expectations about future events. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as “believe,” “expects,” “may,” “will,” “could,” “should,” “shall,” “risk,” “intends,” “estimates,” “aims,” “plans,” “predicts,” “continues,” “assumes,” “positioned” or “anticipates” or the negative thereof, other variations thereon or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. Forward-looking statements may and often do differ materially from actual results. No assurance can be given that such future results will be achieved, that any private placement of senior unsecured notes will occur following the investor calls or, regardless of whether a private placement of senior unsecured notes is consummated, that any ratings agencies will upgrade Avolon to investment grade. Avolon does not intend, and undertakes no duty, to update any information contained herein to reflect future events or circumstances, except as required by applicable law.

Ross O’Connor

Head of Investor Relations

[email protected]

T: +353 1 231 5818

Emmet Moloney

Head of Communications

[email protected]

T: +353 1 556 4429

Jonathan Neilan

FTI Consulting

[email protected]

M: +353 86 231 4135

KEYWORDS: Europe Ireland Caribbean Cayman Islands

INDUSTRY KEYWORDS: Professional Services Air Transport Other Travel Finance Travel

MEDIA:

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

PR Newswire

LUND, Sweden and SEATTLE, Nov. 16, 2020 /PRNewswire/ — Alligator Bioscience (“Alligator”) (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy and Aptevo Therapeutics Inc. (“Aptevo”) (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today provided an update on ALG.APV-527, a novel immunotherapeutic bispecific candidate intended for the treatment of multiple solid tumors expressing 5T4, a tumor-restricted antigen.

Aptevo and Alligator are advancing ALG.APV-527 into Phase I clinical development in a co-development 50/50 partnership. The companies anticipate filing a Clinical Trial Authorization during the first half of 2021 to initiate Phase I clinical development in multiple sites in the European Union. Aptevo and Alligator will continue to explore licensing opportunities as ALG.APV-527 moves into clinical development.

“We are very excited about taking ALG.APV-527 into the clinic now, as recent APVO436 complete remission data in two patients in cohort 6 of that Phase I clinical trial speaks to the potential of our ADAPTIR platform. As a potential first-in-class molecule, ALG.APV-527 showcases the versatility of our ADAPTIR platform in generating bispecific antibodies with unique mechanisms of action and a therapeutic profile that is more consistent with traditional antibodies, including an extended half-life, desirable antibody-like manufacturing characteristics and optimized for potency and stability,” said Mr. Marvin White, President and CEO of Aptevo.

“Our collaboration with Alligator Bioscience continues to yield encouraging data supporting the potential advantages of this novel pathway for targeted immunotherapy of cancer. For these reasons, and given recent improvements in our financial position, we are excited to advance this asset into the clinic with the desire to enable potential additional value creation for shareholders as we develop the asset,” concluded Mr. White.

“Aptevo’s clinical candidate APVO436 is based on the same ADAPTIR platform as ALG.APV-527. It is my belief that the response data observed in the APVO436 Phase I trial validates the bispecific format of ALG.APV-527, and strengthens our view that it has the potential to become a successful cancer therapy,” said Per Norlén, CEO of Alligator Bioscience.

ALG.APV-527 is designed to simultaneously target 5T4 and the co-stimulatory receptor 4-1BB (CD137) to promote potent, tumor-directed immune T-cell activation. 5T4 is a well-defined tumor antigen expressed on many different types of malignancies including non-small cell lung, renal, pancreatic, prostate, breast, colorectal, gastric, ovarian and cervical cancers and mesothelioma. Conversely, 5T4 has limited expression on adult normal tissues, making it an attractive target for cancer immunotherapy.

Presentation at the SITC 35th Annual Meeting

As announced on Monday, November 9, Aptevo is presenting two new posters at the Society for Immunotherapy of Cancer’s (SITC) 35th Virtual Annual Meeting, including one on ALG.APV-527. The poster will present preclinical data demonstrating that ALG.APV-527 has a potentially favorable safety profile with no indication of systemic immune activation or liver toxicity in NHP or murine models. ALG.APV-527 induces robust in vitro killing of tumors that is dependent on 5T4 engagement. In vivo, ALG.APV-527 augmented anti-tumor responses and promoted tumor-specific memory.

Details of the Poster Presentation are as follows:


ALG.APV-527: Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4-1BB x 5T4 ADAPTIR bispecific antibody

The abstracts and the accompanying posters will be available in the Virtual Poster Hall to registered attendees from 8:00 am EST on Monday, November 9, until the Virtual Poster Hall closes on December 31, 2020 on the SITC abstract website

About ALG.APV-527

ALG.APV-527 is a novel immunotherapeutic bispecific candidate intended for the treatment of multiple solid tumors expressing 5T4, a tumor-restricted antigen. 5T4 is an antigen that is highly expressed in a large percentage of solid tumors, including, non-small cell lung cancer (NSCLC), head and neck cancer and mesothelioma. ALG.APV-527 is designed to activate anti-tumor responses by inducing signaling through the co-stimulatory receptor 4-1BB (CD137), which is an immune receptor that is upregulated on activated T cells and natural killer (NK) cells.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company’s lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed based on the Company’s versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR™ platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer. For more information, please visit www.aptevotherapeutics.com

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc.). In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com.

For Further Information:

Alligator Bioscience

Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: [email protected] 

The information was submitted for publication, through the agency of the contact person set out above, at 2:00 p.m. CET (8:00 a.m. EST) on November 16, 2020.

Aptevo Therapeutics

Elif McDonald

Senior Director, Investor Relations and Corporate Communications
Phone: 206.859.6616
E-mail: [email protected]

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding our expectations about the timing of the filing of a Clinical Trial Authorization for ALG.APV-527, our intention to continue to explore licensing opportunities for ALG.APV-527, our intention to advance ALG.APV-527 into Phase I clinic development and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances. 

There are a number of important factors that could cause Aptevo’s actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo’s business or prospects; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and enrollment of future clinical trials, availability and timing of data from ongoing clinical trials, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company’s product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the novel coronavirus (referred to as COVID-19). Additional risks and factors that may affect results are set forth in Aptevo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as filed on March 25, 2020 and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo’s expectations in any forward-looking statement.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/alligator-bioscience/r/aptevo-therapeutics-and-alligator-bioscience-advancing-the-bispecific-4-1bbx5t4-antibody-alg-apv-527,c3237662

The following files are available for download:


https://mb.cision.com/Main/12681/3237662/1335532.pdf

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Cision View original content:http://www.prnewswire.com/news-releases/aptevo-therapeutics-and-alligator-bioscience-advancing-the-bispecific-4-1bbx5t4-antibody-algapv-527-into-phase-i-clinical-development-301173602.html

SOURCE Alligator Bioscience

Magal Security Systems Ltd. Reports Third Quarter 2020 Financial Results

PR Newswire

YEHUD, Israel, Nov. 16, 2020 /PRNewswire/ — Magal Security Systems, Ltd. (NASDAQ: MAGS) today announced its financial results for the three and nine months ended September 30, 2020. Management will hold a conference call later today (at 10 a.m. Eastern Time) to discuss the results.

Third Quarter 2020 Results Summary (all comparisons are to the third quarter of 2019)

  • Revenue of $18.3 million compared to $22.2 million
  • Gross margin 41.8% compared to 45.1%
  • Operating income of $0.9 million compared to $2.5 million
  • Net income attributable to Magal’s shareholders of $0.6 million compared to $1.3 million
  • EBITDA of $1.3 million, or EBITDA margin of 7.3% compared to $3.1 million, or EBITDA margin of 13.8%

  • $53.4 million, or $2.31 per share, of cash and cash equivalents, short-term deposits and restricted cash and deposits, net of short-term credit, compared to $51.6 million, or $2.23 per share at year-end 2019

Mr. Dror Sharon, Chief Executive Officer of Magal, commented, “Globally, the Magal team is executing well, despite the impact of COVID restrictions. We are closing sales in the Magal Integrated Solutions (projects) and Senstar Products divisions, with backlog improving to a record level. Magal has remained profitable in every quarter of 2020 and preserved cash without restricting investments in sales and R&D, our primary growth drivers. Investments in new products and upgrades to our core platforms have continued throughout 2020, allowing the Company to maintain a competitive advantage and grow our business. With a strong balance sheet, industry-leading technological expertise and record backlog, Magal is positioned for recovery and growth post-COVID. I remain confident in our ability to execute our long-term strategy to grow revenue, improve profitability and close M&A opportunities.”

Third Quarter 2020 Results

Revenue was $18.3 million compared with revenue of $22.2 million in the third quarter of 2019. Revenue from Magal’s Integrated Solutions division (projects) represented approximately 54% of total revenue, while external revenue from the Senstar Products division represented approximately 46% of total revenue. The decline in revenue was primarily due to the impact of COVID-19 on projects execution and delivery, as well as a slowdown in product and software orders in certain territories. Revenues, not including inter-company revenues, from Magal’s Integrated Solutions (projects) division and Senstar Products division decreased by 26% and 5%, respectively, compared to the third quarter of 2019.

Gross profit was $7.6 million, or 41.8% of revenue in the third quarter of 2020 compared with gross profit of $10.0 million, or 45.1% of revenue, in the year-ago period. The decrease in gross margin in the quarter was primarily due to the higher share of sales from the Magal Integrated Solutions division, which carry a lower gross margin than Senstar product sales, partially offset by the reduction in division revenue and gross profitability.

Operating expense decreased by 9% to $6.8 million in the third quarter of 2020 compared to $7.5 million in the third quarter of 2019. The decline in operating expense was primarily due to deferred new hiring, reduction in travel expenses and ongoing cost efficiency measures.

Operating income was $0.9 million in the third quarter of 2020 compared to $2.5 million in the third quarter of 2019.

Financial income was $0.0 million in the third quarter of 2020 compared to a financial loss of $0.6 million in the third quarter of 2019, which was a non-cash expense as a result of the end of period valuation of monetary assets and liabilities.

Net income attributable to Magal shareholders was $0.6 million, or $0.01 per share, compared to $1.3 million, or $0.06 per share in the third quarter of 2019.

EBITDA for the third quarter was $1.3 million compared with $3.1 million in the third quarter of 2019.

Cash and cash equivalents, short term deposits and restricted cash and deposits, net of short-term credit as of September 30, 2020, was $53.4 million, or $2.31 per share, compared with cash and short-term deposits of $51.6 million, or $2.23 per share, at December 31, 2019.

Investors Conference Call Information

The Company will host a conference call later today, November 16, 2020. The call will begin promptly at: 10:00 am Eastern Time; 5:00 pm Israel Time; 3:00 pm UK Time.

To participate, please call one of the following teleconferencing numbers:

  • US: 1-877-407-9716

  • Israel: 1-809-406-247
  • UK: 0-800-756-3429
  • International: 1-201-493-6779

The conference call will also be webcast live at http://public.viavid.com/index.php?id=142299.

A replay link of the call will be available at www.magalsecurity.com on November 16, 2020 after 1:00 pm Eastern time through November 30, 2020 at 11:59 pm Eastern time. The Replay Pin Number is 13712737.

About Magal Security Systems Ltd.

Magal is a leading international provider of physical and video security solutions and products, as well as site management. Since 1969, Magal has delivered its products as well as tailor-made security solutions and turnkey projects to hundreds of satisfied customers in over 100 countries – under the most challenging conditions.

Magal offers comprehensive integrated solutions for critical sites, managed by Fortis4G – our 4th generation, cutting-edge physical security information management system (PSIM). The solutions leverage our broad portfolio of home-grown solutions including, PIDS (Perimeter Intrusion Detection Systems) and Symphony, our advanced VMS (Video Management Software) with native IVA (Intelligent Video Analytics) security solutions.

Forward Looking Statements

This press release contains forward-looking statements, which are subject to risks and uncertainties. Such statements are based on assumptions and expectations which may not be realized and are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy and some of which might not even be anticipated. Future events and actual results, financial and otherwise, may differ from the results discussed in the forward-looking statements. A number of these risks and other factors that might cause differences, some of which could be material, along with additional discussion of forward-looking statements, are set forth in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission. In addition, there is uncertainty about the impact of the spread of the COVID19 virus and its effect on the Company’s operations, the demand for Company’s products, global supply chains and economic activity in general.

For more information:


Magal Security Systems Ltd.


Diane Hill, Assistant to the CEO

Tel: +972-3-539-1421

E-mail: [email protected]

Web: www.magalsecurity.com


IR Contact:

Brett Maas Managing Partner Hayden IR

+1 646-536-7331


[email protected]

 

 


MAGAL SECURITY SYSTEMS LTD.


UNAUDITED CONDENSED CONSOLIDATED
 STATEMENTS OF OPERATIONS


(All numbers except EPS expressed in thousands of US$)


Three Months


Ended September 30,


Nine Months


Ended September 30,



2020



2019



% change



2020



2019



% change


Revenue


18,254


22,188


(18)


52,064


63,075


(17)


Cost of revenue


10,629


12,187


(13)


29,216


35,710


(18)


Gross profit


7,625


10,001


(24)


22,848


27,365


(17)


Operating expenses:

   Research and development, net

1,304

1,285


1

4,237

4,833


(12)

   Selling and marketing

3,086

4,026


(23)

9,924

12,534


(21)

   General and administrative

2,385

2,169


10

6,804

6,810


(0)

Total operating expenses


6,775


7,480


(9)


20,965


24,177


(13)


Operating income


850


2,521


1,883


3,188

Financial income (expenses), net

6

(573)

19

(1,667)


Income before income taxes


856


1,948


1,902


1,521

Taxes on income

587

438

970

975


Net income


269


1,510


932


546

Income (loss) attributable to redeemable non-controlling
interests and non-controlling interests

(347)

212

(276)

36


Net income attributable to Magal’s shareholders


616


1,298


1,208


510


Basic and diluted net income per share


$0.01


$0.06


$0.03


$0.02


Weighted average number of shares used in computing
basic net income per share


23,153,985


23,153,985


23,153,985


23,121,107


Weighted average number of shares used in computing
diluted net income per share


23,153,985


23,167,049


23,153,985


23,141,574


Three Months


Ended September 30,


Nine Months


Ended September 30,



2020



%



2019



%



2020



%



2019



%

Gross margin

41.8

45.1

43.9

43.4

Research and development, net as a % of revenues

7.1

5.8

8.1

7.7

Selling and marketing as a % of revenues

16.9

18.1

19.1

19.9

General and administrative as a % of revenues

13.1

9.8

13.1

10.8

Operating margin

4.7

11.4

3.6

5.1

Net margin

3.4

5.9

2.3

0.8

 


MAGAL SECURITY SYSTEMS LTD.


 
RECONCILLATION OF EBITDA TO NET INCOME


(All numbers expressed in thousands of US$)


Three Months


Ended September 30,


Nine Months


Ended September 30,



2020



2019



2020



2019


GAAP Net income


269


1,510


932


546

   Less:

   Financial income (expenses), net

6

(573)

19

(1,667)

   Taxes on income

(587)

(438)

(970)

(975)

   Depreciation and amortization

(489)

(542)

(1,456)

(1,591)

EBITDA


1,339


3,063


3,339


4,779

 

 


MAGAL SECURITY SYSTEMS LTD.


UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS


(All numbers expressed in thousands of US$)


September 30,


December 31,


2020


2019


CURRENT ASSETS:

Cash and cash equivalents

$53,655

$34,531

Short-term bank deposits

16,749

Restricted cash and deposits

257

324

Trade receivables, net

12,604

18,697

Unbilled accounts receivable

8,628

8,897

Other accounts receivable and prepaid expenses

4,650

4,510

Inventories

14,412

12,605


Total current assets


94,206


96,313

 

Long term investments and receivables:

Long-term deposits, restricted bank deposits and other long-term accounts
receivable and prepaid expenses

127

134

Severance pay fund

1,413

1,363

Deferred tax assets

3,998

4,215

Operating lease right-of-use assets

2,774

3,492


Total long-term investments and receivables


8,312


9,204


PROPERTY AND EQUIPMENT, NET


5,923


6,256


GOODWILL AND INTANGIBLE ASSETS, NET


14,383


15,276

Total assets


$122,824


$127,049

 

 


MAGAL SECURITY SYSTEMS LTD.


UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS


(All numbers expressed in thousands of US$)


September 30,


December 31,


2020


2019


CURRENT LIABILITIES:

Short-term credit

$529

$       –

Trade payables

4,297

5,438

Customer advances

4,696

5,587

Deferred revenues

2,208

2,558

Other accounts payable and accrued expenses

12,574

14,609

Short-term operating lease liabilities

702

919


Total current liabilities


25,006


29,111

LONG-TERM LIABILITIES:

Deferred revenues

2,148

1,769

Deferred tax liabilities

197

178

Accrued severance pay

2,245

2,251

Long-term operating lease liabilities

2,030

2,515

Other long-term liabilities

269

371


Total long-term liabilities


6,889


7,084


Redeemable non-controlling interest


3,218


3,048


SHAREHOLDERS’ EQUITY

Share Capital: Ordinary shares of NIS 1 par value –

Authorized: 39,748,000 shares at September 30, 2020 and December 31,
2019; Issued and outstanding: 23,153,985 shares at September 30, 2020 and
23,153,985 shares at December 31, 2019

6,750

6,750

Additional paid-in capital

94,858

94,696

Accumulated other comprehensive loss

(1,891)

(627)

Foreign currency translation adjustments (stand-alone financial statements)

6,158

5,924

Accumulated deficit

(18,162)

(18,961)

Total shareholders’ equity

87,713

87,782

Non-controlling interest

(2)

24


TOTAL SHAREHOLDERS’ EQUITY


87,711


87,806


TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY


$122,824


$127,049

Cision View original content:http://www.prnewswire.com/news-releases/magal-security-systems-ltd-reports-third-quarter-2020-financial-results-301173601.html

SOURCE Magal Security Systems, Ltd.

Camping World Announces Entry Into North Dakota with Agreement to Acquire Outlet Recreation

Camping World Announces Entry Into North Dakota with Agreement to Acquire Outlet Recreation

LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–
Camping World Holdings, Inc. (NYSE: CWH) (“Camping World”), the nation’s largest network of RV and outdoor lifestyle – centric retail locations, today announced an agreement to acquire the Outlet Recreation dealership based in the Fargo market. This acquisition marks the Company’s first location in North Dakota, with plans for the deal to close in December 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116005291/en/

Camping World RV SuperCenter (Photo: Business Wire)

Camping World RV SuperCenter (Photo: Business Wire)

“We are well-positioned to remain a leader in the RV industry as it continues to evolve,” said Marcus Lemonis, Chairman of Camping World. “The addition of Outlet Recreation in Fargo will allow us to expand our footprint into the state of North Dakota while continuing to deliver a high standard of customer service and integrity in the industry.”

Located in West Fargo, ND off I-94, Outlet Recreation offers a wide range of new and used travel trailers, fifth wheels and motorhomes from top manufacturers and brands. This acquisition is in line with the Company’s future growth plans.

“I’m proud of the network that Camping World has built over the last few years, and we are not even close to reaching our potential,” continued Lemonis. “As we enter our 38th state, we are laser focused on being in all 48 continental states by the end of 2021, which will help us execute our goal of selling RVs seamlessly online, to complement our physical retail locations.”

Camping World currently owns and operates over 160 SuperCenters nationwide, specializing in RV sales and service, RV parts and accessories, outdoor lifestyle products and its entire portfolio of Good Sam products and services. From new strategic acquisitions, new store development and facility upgrades, the Company’s network will continue to expand and evolve while serving its customers’ outdoor, RV and camping needs.

Camping World is always looking for seasoned and professional RV sales associates, technicians, and retail support to assist with locations across the country. Individuals interested in applying for a position with Camping World may visit http://www.campingworldcareers.com/.

About Camping World Holdings, Inc.

Camping World Holdings, headquartered in Lincolnshire, Illinois, is America’s leading recreational vehicle and outdoor retailer, offering an extensive assortment of recreational vehicles for sale, RV and camping gear, RV maintenance and repair, other outdoor and active sports products, and the industry’s broadest and deepest range of services, protection plans, products and resources. Since the Company’s founding in 1966, Camping World has grown to become one of the most well-known destinations for everything RV, with more than 160 locations in 37 states and a comprehensive e-commerce platform. For more information, visit www.CampingWorld.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Camping World and other matters. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding our future results of operations and financial position, our capital return strategy, and expected dividend payments are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expects,’’ ‘‘plans,’’ ‘‘anticipates,’’ ‘‘could,’’ ‘‘intends,’’ ‘‘targets,’’ ‘‘projects,’’ ‘‘contemplates,’’ ‘‘believes,’’ ‘‘estimates,’’ ‘‘predicts,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. You should carefully consider the risks and uncertainties that affect our business, including the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K filed for the year ended December 31, 2019, as updated in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and our other reports filed with the SEC. These forward-looking statements speak only as of the date of this communication. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our public announcements and filings with the Securities and Exchange Commission.

Karen Porter [email protected]

KEYWORDS: United States North America North Dakota Illinois

INDUSTRY KEYWORDS: Transportation Travel Automotive Specialty Vacation Recreational Vehicles General Automotive Retail

MEDIA:

Photo
Photo
Camping World RV SuperCenter (Photo: Business Wire)
Logo
Logo